Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 5;12(8):726.
doi: 10.3390/metabo12080726.

Blood and Urinary Biomarkers of Antipsychotic-Induced Metabolic Syndrome

Aiperi K Khasanova  1 , Vera S Dobrodeeva  1 , Natalia A Shnayder  1   2 , Marina M Petrova  2 , Elena A Pronina  2 , Elena N Bochanova  2 , Natalia V Lareva  3 , Natalia P Garganeeva  4 , Daria A Smirnova  5 , Regina F Nasyrova  1   5
Affiliations
Review

Blood and Urinary Biomarkers of Antipsychotic-Induced Metabolic Syndrome

Aiperi K Khasanova et al. Metabolites. .

Abstract

Metabolic syndrome (MetS) is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). Antipsychotic (AP)-induced MetS (AIMetS) is the most common adverse drug reaction (ADR) of psychiatric pharmacotherapy. Herein, we review the results of studies of blood (serum and plasma) and urinary biomarkers as predictors of AIMetS in patients with schizophrenia (Sch). We reviewed 1440 studies examining 38 blood and 19 urinary metabolic biomarkers, including urinary indicators involved in the development of AIMetS. Among the results, only positive associations were revealed. However, at present, it should be recognized that there is no consensus on the role of any particular urinary biomarker of AIMetS. Evaluation of urinary biomarkers of the development of MetS and AIMetS, as one of the most common concomitant pathological conditions in the treatment of patients with psychiatric disorders, may provide a key to the development of strategies for personalized prevention and treatment of the condition, which is considered a complication of AP therapy for Sch in clinical practice.

Keywords: antipsychotic-induced metabolic syndrome; antipsychotics; metabolic syndrome; personalized metabolomics; personalized psychiatry; serum biomarkers; urinary biomarkers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Potential Blood (Serum and Plasma) and Urinary Biomarkers of Antipsychotics—Induced Metabolic Syndrome (AIMetS) in Patients with Schizophrenia (Sch).
Figure 2
Figure 2
Potential Blood (Serum and Plasma) and Urinary Biomarkers of Antipsychotics—Induced Metabolic Syndrome (AIMetS) in Patients with Schizophrenia (Sch).
Figure 3
Figure 3
Algorithm of Personalized Approach to the Diagnosis of Antipsychotics—Induced Metabolic Syndrome (AIMetS) in Patients with Schizophrenia (Sch) Based on Blood and Urinary Biomarkers: Definite, Probable and Possible AIMetS.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486. - DOI - PubMed
    1. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Jr., et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404. - DOI - PubMed
    1. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.C., James W.P., Loria C.M., Smith S.C. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645. - PubMed
    1. Hanley A.J., Karter A.J., Williams K., Festa A., D’Agostino R.B., Jr., Wagenknecht L.E., Haffner S.M. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: The Insulin Resistance Atherosclerosis Study. Circulation. 2005;112:3713–3721. doi: 10.1161/CIRCULATIONAHA.105.559633. - DOI - PubMed
    1. Kannel W.B., McGee D., Gordon T. A general cardiovascular risk profile: The Framingham Study. Am. J. Cardiol. 1976;38:46–51. doi: 10.1016/0002-9149(76)90061-8. - DOI - PubMed